The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...

There isn't a cure for the condition, but doctors may recommend medications to slow down the progression of the disease or ...

Diabetes is a common, lifelong condition that occurs when the pancreas doesn't produce enough insulin, or when the body is unable to effectively use the insulin it produces ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...